Skip to content
Menu

Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Piper Sandler analyst David Amsellem reiterates Pelthos Therapeutics (AMEX:PTHS) with a Overweight and lowers the price target from $48 to $21.

Piper Sandler analyst David Amsellem reiterates Pelthos Therapeutics (AMEX:PTHS) with a Overweight and lowers the price target from $48 to $21.

Read at benzinga.com